McEwan P - Search Results

1

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review.

Darlington O, Dickerson C, Evans M, McEwan P, Sörstadius E, Sugrue D, van Haalen H, Garcia Sanchez JJ. Darlington O, et al. Among authors: mcewan p. Adv Ther. 2021 Feb;38(2):994-1010. doi: 10.1007/s12325-020-01607-4. Epub 2021 Jan 11. Adv Ther. 2021. PMID: 33432542 Free PMC article. Review.

2

Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.

Evans M, McEwan P, Peters JR, Currie CJ. Evans M, et al. Among authors: mcewan p. Diabetes Obes Metab. 2004 Jul;6(4):299-307. doi: 10.1111/j.1462-8902.2004.00340.x. Diabetes Obes Metab. 2004. PMID: 15171755 Review. No abstract available.

3

Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus.

Cockcroft JR, Wilkinson IB, Evans M, McEwan P, Peters JR, Davies S, Scanlon MF, Currie CJ. Cockcroft JR, et al. Among authors: mcewan p. Am J Hypertens. 2005 Nov;18(11):1463-7; discussion 1468-9. doi: 10.1016/j.amjhyper.2005.05.009. Am J Hypertens. 2005. PMID: 16280282

4

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model.

McEwan P, Evans M, Kan H, Bergenheim K. McEwan P, et al. Diabetes Obes Metab. 2010 May;12(5):431-6. doi: 10.1111/j.1463-1326.2009.01184.x. Diabetes Obes Metab. 2010. PMID: 20415691

5

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes.

McEwan P, Evans M, Bergenheim K. McEwan P, et al. Diabetes Obes Metab. 2010 Jul;12(7):623-30. doi: 10.1111/j.1463-1326.2010.01198.x. Diabetes Obes Metab. 2010. PMID: 20590737

6

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.

Evans M, McEwan P, O'Shea R, George L. Evans M, et al. Among authors: mcewan p. Diabetes Ther. 2013 Jun;4(1):27-40. doi: 10.1007/s13300-012-0015-6. Epub 2012 Dec 8. Diabetes Ther. 2013. PMID: 23225378 Free PMC article.

7

Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom.

Gordon J, Evans M, McEwan P, Bain S, Vora J. Gordon J, et al. Among authors: mcewan p. Diabetes Ther. 2013 Jun;4(1):51-66. doi: 10.1007/s13300-012-0018-3. Epub 2013 Jan 8. Diabetes Ther. 2013. PMID: 23296753 Free PMC article.

8

Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.

van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. van Haalen HG, et al. Among authors: mcewan p. Clin Drug Investig. 2014 Feb;34(2):135-46. doi: 10.1007/s40261-013-0155-0. Clin Drug Investig. 2014. PMID: 24243529 Clinical Trial.

9

Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation.

Evans M, McEwan P, Foos V. Evans M, et al. Among authors: mcewan p. J Med Econ. 2015 Feb;18(2):96-105. doi: 10.3111/13696998.2014.975234. Epub 2014 Oct 29. J Med Econ. 2015. PMID: 25325179 Free article.

10

Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration.

McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. McEwan P, et al. Med Decis Making. 2015 Jul;35(5):660-70. doi: 10.1177/0272989X14565821. Epub 2015 Jan 16. Med Decis Making. 2015. PMID: 25596535

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters